• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Akebia Therapeutics (NQ: AKBA )

    1.660 -0.040 (-2.35%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Akebia Therapeutics

    Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
    Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
    Via MarketBeat
    Exposures Product Safety
    Akebia Therapeutics Inc. (NASDAQ: AKBA) is One of Thursday Morning’s Most Active Stocks
    Via Investor Brand Network
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
    Via TheNewswire.com
    How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
    Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
    Via TheNewswire.com
    Exposures Product Safety
    Akebia Therapeutics, Inc. (NASDAQ:AKBA) Long Term Investor Alert: Investigation of Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 06/20/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akebia Therapeutics, Inc.. 
    Via SBWire
    AKEBIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    NASDAQ:AKBA Investor Notice: Deadline on May 13, 2022 in Lawsuit Against Akebia Therapeutics, Inc.
    San Diego, CA -- (SBWIRE) -- 05/10/2022 -- The Shareholders Foundation announced that a deadline is coming up on May 13, 2022 in the lawsuit filed for certain investors of Akebia Therapeutics, Inc.... 
    Via SBWire
    AKBA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 Deadline
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AKBA INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action AKBA
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    NASDAQ:AKBA Investor Notice: Lawsuit Alleges Securities Laws Violations by Akebia Therapeutics, Inc.
    San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia... 
    Via SBWire
    Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
    From Rosen Law Firm
    Via Business Wire
    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
    Via AB Newswire
    Topics Bonds Stocks
    Exposures Debt Markets US Equities
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger
    From Robbins LLP
    Via Business Wire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Akebia Therapeutics, Inc. (NASDAQ: AKBA) Investor Alert: Investigation over Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares over potential wrongdoing at Akebia Therapeutics, Inc was announced... 
    Via SBWire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.